A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer

BACKGROUND: Preclinical and early clinical data support the use of Vascular Epithelial Growth Factor (VEGF)-targeted therapy with trastuzumab in Human Epidermal Receptor 2 (HER2) positive breast cancer. Adding bevacizumab to a taxane (docetaxel or paclitaxel) improves progression free survival (PFS)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Zhao, Meng, Pan, Xueliang, Layman, Rachel, Lustberg, Maryam B., Mrozek, Ewa, Macrae, Erin R., Wesolowski, Robert, Carothers, Sarah, Puhalla, Shannon, Shapiro, Charles L., Ramaswamy, Bhuvaneswari
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4303337/
https://ncbi.nlm.nih.gov/pubmed/24894652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0122-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars